Clinical Trial Update: The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating an oral hexavalent reassortant rotavirus vaccine produced in Vero cells has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Gastroenteritis

Drugs mentioned

• Oral Hexavalent Reassortant Rotavirus Vaccine (Vero Cells) (rotavirus vaccine, live attenuated, hexavalent reassortant)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Rotavirus Gastroenteritis | Phase 1 | Status: COMPLETED